The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Abstract
Local mRNA therapy encoding inflammatory cytokines and T cell costimulator OX40L mediates persistent anticancer immunity across tumor models.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alternatively to vaccination, a pro-inflammatory tumour microenvironment can be induced by lipid nanoparticle–mRNA formulations delivering cytokines or co-stimulatory molecules33,106,161,163,214 (Table 2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [163]
In the citing paper
“Encouraged by these results, mRNA-2752, a lipid nanoparticle formulated with mRNA encoding human OX40L, IL-23 and IL-36γ, entered clinical evaluation (NCT03739931)163,215,216.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [163]
In the citing paper
“In line with this, Moderna Therapeutics recently published on an anti-cancer immunotherapy, using direct intratumoral-and LNP-mediated delivery of a mixture of mRNA encoding IL-23, IL-36γ, and OX40(L) ligand [203].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [203]
In the citing paper
“By the localized expression of these immunomodulatory molecules, this strategy was able to break DC tolerance and to activate tumor-specific T cell responses.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [203]
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,030
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
Cited by
Sorted by citations
Items 301–317 of 317
Li, S., Zhang, Y., Han, Y., Zhao, M., Wang, Y., Lu, J., Li, R., Wang, R., Shan, R., You, W., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.002
mRNA trends in cancer therapeutics
Joneidi, F., Sabouri, M., Mohsen-Pour, N., & Sharafi, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43870-7.00003-5
Advances in RNA-Based Therapeutics in Oncology
Lopes-Cardoso, H., Panão-Costa, J., Amaral, A. T., Soares-Gonçalves, J., Neves, B. F., Voronovska, A., Batista, A., Biscaia-Caleiras, M., Fonseca, N. A., Simões, S., et al. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_19
Bian, H., Tse, W. W., Huang, G., & Liu, S. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag019
Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy
Lin, X., Li, Y., Shen, X., Li, B., & Xu, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.007
Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer
Fernández-Luna, C., Baena-, J., Calles, A., Antoñanzas, M., Lage, Y., Mielgo-Rubio, X., Sereno-Moyano, M., Cervera, R., Cabezón‐Gutiérrez, L., López, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016133
In situ vaccination for the treatment of localized cancer and the prevention of metastatic disease
Lee, S., Kim, M., Wang, Y., Johnson, B., & You, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862956
Guo, Y., Wang, M., Xuan, Y., Pan, L., Yan, W., Cheng, J., Yu, Y., Wang, X., Xu, L., Sun, X., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016326
Liposomal nanoparticle mediated gene modulation for the treatment of melanoma in murine models
Yadav, P., Kelly, P. J., Mandal, S. K., Williams, M. L., Tang, B., McWatters, A., & Sheth, R. A. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2738804
van der Walle, C. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45791-3.00005-6
The expression window as a safety parameter for mRNA medicines
Tani, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118513
Rehman, A. U., Khan, M. A.-U.-R., Akhtar, A., Qin, Q., Zhang, X. X., Asghar, M. A., Ling, D., Wang, P., Luo, Y., Wang, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-017160
Zhou, X.-J., Zhu, J.-C., Dong, J., Yan, S.-Y., Si-yin, Z., Dong, J.-T., Zhang, B.-Q., Che, H.-R., Zhang, C.-H., Zhang, R., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1957469
Tian, L., Lin, Z., Ma, J., Hu, Z., Cao, N., Chen, X., Lu, M., Liu, S., Zhang, C., Chen, H., et al. (2026) · Transboundary and Emerging Diseases · doi:10.1155/tbed/2092704
Wang, Y., Ge, Y., Chen, Y., 杨永峰, & Li, J. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01857-9
Programmable mRNA vaccine materials for temporal control of antitumour immunity
Jeong, S. D., Tang, C., Wang, X., Szeglowski, A., Kim, Y., Kim, B., Sharma, P., Moon, J. J., Jiang, W., & Kim, B. Y. S. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00974-8
Yi, S., Seo, E., Park, P., & Hong, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.2007961
Metadata
- Authors
- Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., Bhatt, K., Garnaas, M., Musenge, F., Davis, A., Khatwani, N., Su, S. V., MacLean, G., Farlow, S. J., Burke, K., & Frederick, J. P.
- Affiliations
- Moderna Inc., 200 Technology Square, Cambridge, MA 02139, USA.
- Corresponding author
- Hewitt, Susannah L.
- Bai, Ailin
- Frederick, Joshua P.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-01-30
- Volume
- 11
- Issue
- 477
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2912510115
- Cited by
- 316
- References
- 55
- Citations by year
- 2026: 41 · 2025: 54 · 2024: 51 · 2023: 57 · 2022: 39 · 2021: 41 · 2020: 26 · 2019: 6
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Moderna Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- IL-23, IL-36γ, OX40L, cancer immunotherapy, tumor-infiltrating T cells, immune checkpoint inhibitor resistance, tumor microenvironment
- MeSH terms
- Animals, Disease Models, Animal, Humans, Immunity, Inflammation, Interleukin-1, Lymph Nodes, Lymphocyte Activation, Neoplasms, RNA, Messenger, Tissue Distribution, Cell Proliferation, Mice, OX40 Ligand, Interleukin-23, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
